Analyst Projecting 50% Upside in Dendreon (DNDN)
Dendreon Corporation (NASDAQ: DNDN) was started with a Buy rating and a $36.00 target at Deutsche Bank. The call’s positive expectations are mixed near-term, but the assumption is that Provenge will become a blockbuster product in the fight against metastatic…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Deutsche Bank believes that Dendreon will receive approval in early 2010. The firm does note that near term stock trading may remain range-bound into an the FDA Approval process. There is a summer analyst meeting where the firm expects Dendreon to provide details on manufacturing and on the company’s marketing strategy.
The expectation is that the approval process will be filed in late 2009 with a subsequent approval in early 2010. Interestingly enough, Deutsche Bank notes that investors are likely placing too little value on the FDA approval chances. It also noted that an additional approval in the European Union is not reflected in the shares.
Dendreon is already indicated higher with more than two hours to go before the opening bell. After a $25.46 close on Thursday, shares are looking up around the $26.75 level. The 52-week range is $2.55 to $27.40.
Jon C. Ogg
June 5, 2009
Contact [email protected] for any questions or corrections.
Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.
McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.
His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.
A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.
TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.
McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.
